<b>Objectives:</b> Since postoperative narcotics have been associated with the risk of long-term opioid use, they are no longer prescribed at our institution for patients undergoing robotic surgery for endometrial hyperplasia or endometrial carcinoma. This study compared postoperative narcotic use in the current cohort with a historical cohort who were prescribed postoperative opioids to assess the effect of the change in practice. <b>Methods:</b> We performed a retrospective chart review of 123 patients who underwent a robotic hysterectomy for endometrial hyperplasia or carcinoma. Group 1 patients underwent surgery between August 2017 and February 2018 and received opioid prescriptions. Group 2 underwent surgery between January and June 2020 and did not receive postoperative opioid prescriptions. We reviewed medical records and the New York State Internet System for Tracking Over-Prescribing (I-STOP), which reports all narcotic prescriptions filled in the state in the past 12 months. Narcotic use was assessed in one- month intervals for a total of 12 months after surgery. Demographic information, including diagnosis, histology, adjuvant therapy, insurance, median income based on zip code, and medical comorbid conditions, were collected. Results were analyzed using a hierarchical Bayesian ordinal regression model to determine whether Group 2 had a lower risk of opioid use and to evaluate other possible factors. The variable of interest was the time (months) from surgery to the patient filling an opiate prescription. <b>Results:</b> Group 1 had 57 patients, and Group 2 had 66 patients. There was no significant difference in age, median income, cancer stage, grade, histology, or adjuvant therapy between the groups. Group 1 had significantly more patients with private insurance (93% vs 53% p <0.0001) and fewer patients with favorable CCI scores of 1-4 (70% with vs 50%, p 0.02) compared to Group 2; however, only private insurance remained significant after Bonferroni correction. Prescriptions for opioids were filled more often by patients in Group 1 than Group 2 at immediate postop 0-1 months (79% vs 7%), 1-6 months (14% vs 6%) and 6-12 months (17% vs 6%). Opioid use was significantly higher across all measured time frames in patients who were prescribed postoperative opioids with a mean effect size of -0.99 with a 95% credible interval of -1.93 to -0.11. Lower Grade endometrial cancer was also associated with reduced opioid use with a mean effect size of -2.66 with 95% credible interval of -4.7 to -0.45 for Grade 1 and mean effect size -2.18 with 95% credible interval -4.4 to -0.16 for Grade 2. Fig. 1 <b>Conclusions:</b> Eliminating postoperative opioid prescriptions was associated with a significant decrease in both short- and long-term opioid use. While insurance type varied between the two groups, this was not an independent risk factor. The clinical relevance of the association of grade with opioid use is unclear as there was no association with stage or adjuvant therapy. Limitations of our study are the small sample size and possible confounders, including increasing awareness of the opioid crisis and a change in prescribing practices by other providers over time. This study supports avoiding prescribing opioids in the postoperative period.